<DOC>
	<DOC>NCT02690155</DOC>
	<brief_summary>To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting</brief_summary>
	<brief_title>Real-world Comparative Effectiveness of Rivaroxaban Versus VKA</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>NVAF(nonvalvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD(International Classification of Disease)9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics CHA2DS2Vasc score â‰¥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 6574 years; Sc: Sex category) Patients &lt;18 years of age Patients with valvular AF (Atrial fibrillation) Pregnancy Malignant cancers Transient cause of AF Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis) Patients with major surgery defined as hip or knee replacement Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date Prescription of more than one OAC on the index date Patient with any of the events defined in the composite endpoint Fatal bleeding Fatal Stroke/Myocardial infarction Intracranial hemorrhage Ischemic stroke Myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
	<keyword>Prevention</keyword>
	<keyword>Stroke</keyword>
</DOC>